Literature DB >> 30401522

Incorporating newer agents in the treatment of acute myeloid leukemia.

Renju V Raj1, Sameem M Abedin2, Ehab Atallah3.   

Abstract

Prognosis for patients with AML remains dismal. Despite multiple clinical trials across several decades, little improvement for the therapy of non-APL AML was noted. However, over the last couple of years, several new therapies have demonstrated efficacy in the therapy of patients with AML. Several of those have been approved by the FDA for AML therapy. These include CPX-351, midostaurin, gemtuzumab ozogamicin, enasidenib and ivosidenib. Our goal in this review is to summarize currently available data on these new therapies and discuss the rapidly evolving treatment landscape of AML.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  AML; CPX-351; Gemtuzumab; IDH inhibitor; Midostaurin; Venetoclax

Mesh：

Substances：

Year:  2018        PMID： 30401522     DOI： 10.1016/j.leukres.2018.10.008

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  4 in total

1.  A personalized approach to acute myeloid leukemia therapy: current options.

Authors:  Raveen Stephen Stallon Illangeswaran; Saswati Das; Daniel Zechariah Paul; Vikram Mathews; Poonkuzhali Balasubramanian
Journal:  Pharmgenomics Pers Med       Date:  2019-08-02

2.  National burden of cancer in Italy, 1990-2017: a systematic analysis for the global burden of disease study 2017.

Authors:  Cristina Bosetti; Eugenio Traini; Tahiya Alam; Christine A Allen; Giulia Carreras; Kelly Compton; Christina Fitzmaurice; Lisa M Force; Silvano Gallus; Giuseppe Gorini; James D Harvey; Jonathan M Kocarnik; Carlo La Vecchia; Alessandra Lugo; Mohsen Naghavi; Alyssa Pennini; Cristiano Piccinelli; Luca Ronfani; Rixing Xu; Lorenzo Monasta
Journal:  Sci Rep       Date:  2020-12-16       Impact factor: 4.379

3.  RAS activation induces synthetic lethality of MEK inhibition with mitochondrial oxidative metabolism in acute myeloid leukemia.

Authors:  Justine Decroocq; Rudy Birsen; Camille Montersino; Prasad Chaskar; Jordi Mano; Laury Poulain; Chloe Friedrich; Anne-Sophie Alary; Helene Guermouche; Ambrine Sahal; Guillemette Fouquet; Mathilde Gotanègre; Federico Simonetta; Sarah Mouche; Pierre Gestraud; Auriane Lescure; Elaine Del Nery; Claudie Bosc; Adrien Grenier; Fetta Mazed; Johanna Mondesir; Nicolas Chapuis; Liza Ho; Aicha Boughalem; Marc Lelorc'h; Camille Gobeaux; Michaela Fontenay; Christian Recher; Norbert Vey; Arnaud Guillé; Daniel Birnbaum; Olivier Hermine; Isabelle Radford-Weiss; Petros Tsantoulis; Yves Collette; Rémy Castellano; Jean-Emmanuel Sarry; Eric Pasmant; Didier Bouscary; Olivier Kosmider; Jerome Tamburini
Journal:  Leukemia       Date:  2022-03-30       Impact factor: 12.883

Review 4.  Bibliometric analysis of studies about acute myeloid leukemia conducted globally from 1999 to 2018.

Authors:  Beomjun Seo; Jeeyoon Kim; Seungwook Kim; Eunil Lee
Journal:  Blood Res       Date:  2020-03-30
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.